One extra zero added to a bank check can mean the difference between losing $100 and losing $1,000. In many cases, such ...

Securing comparator drugs in the EU is a complex process shaped by availability constraints, regulatory expectations, and competitive market behavior. But if we have the right planning, strong ...

Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...

In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...

There are no salary caps, no aprons, and no luxury taxes, yet the world’s most-watched soccer league is only getting more balanced ...

Oncoscope launches the first Real-time, AI-supported Living Systematic Literature Review designed for enterprise-wide ...

BBAI bets big on secure GenAI with its $250M Ask Sage buy, aiming to leapfrog rivals stuck in FedRAMP certification limbo.

Optum notable drugs nearing FDA approval include Anaphylm, Sotyktu, and insulin icodec with decisions expected early 2026.

Laboratories are no longer peripheral. They are central to modern clinical development - enabling earlier decision-making, ...